↓ Skip to main content

HER2Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma

Overview of attention for article published in American Journal of Clinical Pathology, November 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#4 of 2,557)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
63 news outlets
twitter
5 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
32 Mendeley
Title
HER2Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma
Published in
American Journal of Clinical Pathology, November 2016
DOI 10.1093/ajcp/aqw206
Pubmed ID
Authors

Angela N. Bartley, Mary Kay Washington, Christina B. Ventura, Nofisat Ismaila, Carol Colasacco, Al B. Benson, Alfredo Carrato, Margaret L. Gulley, Dhanpat Jain, Sanjay Kakar, Helen J. Mackay, Catherine Streutker, Laura Tang, Megan Troxell, Jaffer A. Ajani

Abstract

ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA. To establish an evidence-based guideline for HER2 testing in patients with GEA, to formalize the algorithms for methods to improve the accuracy of HER2 testing while addressing which patients and tumor specimens are appropriate, and to provide guidance on clinical decision making. The College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology convened an expert panel to conduct a systematic review of the literature to develop an evidence-based guideline with recommendations for optimal HER2 testing in patients with GEA. The panel is proposing 11 recommendations with strong agreement from the open-comment participants. The panel recommends that tumor specimen(s) from all patients with advanced GEA, who are candidates for HER2-targeted therapy, should be assessed for HER2 status before the initiation of HER2-targeted therapy. Clinicians should offer combination chemotherapy and a HER2-targeted agent as initial therapy for all patients with HER2-positive advanced GEA. For pathologists, guidance is provided for morphologic selection of neoplastic tissue, testing algorithms, scoring methods, interpretation and reporting of results, and laboratory quality assurance. This guideline provides specific recommendations for assessment of HER2 in patients with advanced GEA while addressing pertinent technical issues and clinical implications of the results.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 3%
Unknown 31 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 7 22%
Professor > Associate Professor 5 16%
Student > Postgraduate 3 9%
Researcher 3 9%
Student > Bachelor 2 6%
Other 6 19%
Unknown 6 19%
Readers by discipline Count As %
Medicine and Dentistry 20 63%
Biochemistry, Genetics and Molecular Biology 2 6%
Agricultural and Biological Sciences 1 3%
Economics, Econometrics and Finance 1 3%
Nursing and Health Professions 1 3%
Other 1 3%
Unknown 6 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 500. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 February 2017.
All research outputs
#17,841
of 14,092,834 outputs
Outputs from American Journal of Clinical Pathology
#4
of 2,557 outputs
Outputs of similar age
#990
of 285,360 outputs
Outputs of similar age from American Journal of Clinical Pathology
#1
of 34 outputs
Altmetric has tracked 14,092,834 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,557 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,360 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.